| Literature DB >> 25110633 |
Mussaret Bano Zaidi1, Teresa Estrada-García2.
Abstract
Despite a significant decrease in Shigella-related mortality, shigellosis continues to carry a significant burden of disease worldwide, particularly in Asia and Africa. Shigella is a highly virulent pathogen comprised of four major species with numerous subtypes. Shigella dysenteriae and Shigella flexneri infections are predominant in resource-limited settings. Clinical presentations range from mild watery diarrhea to severe dysentery with systemic complications such as electrolyte imbalance, seizures and hemolytic uremic syndrome. S. dysenteriae subtype 1, the producer of Shiga toxin, causes the most severe illness and highest mortality. Susceptible strains of Shigella may be effectively treated with inexpensive oral antibiotics such as ampicillin or trimethoprim-sulfamethoxazole. Unfortunately, multidrug resistant strains have emerged that have rendered most antibiotics, including fluoroquinolones and extended-spectrum cephalosporins, ineffective. Management and prevention of shigellosis represents a major public health challenge. The development of an effective vaccine is urgently needed to decrease its global impact.Entities:
Keywords: Ipa; Shigella; Type III secretion system; antimicrobial resistance; bacterial; developing countries; epidemiology; extended-spectrum cephalosporins; fluoroquinolones; immune evasion; industrialized countries; morbidity; mortality; serotype switching; socioeconomic conditions; tropical medicine; vaccine; virulence factors
Year: 2014 PMID: 25110633 PMCID: PMC4126259 DOI: 10.1007/s40475-014-0019-6
Source DB: PubMed Journal: Curr Trop Med Rep